Package Leaflet: Information for the User
Abiraterone acetate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Abiraterone Exeltis contains the active substance abiraterone acetate. It is used for the treatment of prostate cancer in adult men that has spread to other parts of the body. This medicine stops your body from making testosterone; this can slow down the growth of your prostate cancer.
When abiraterone is prescribed in the early stages of the disease and you are still responding to hormone treatment, it is used together with a treatment to lower testosterone levels (androgen deprivation treatment).
When you take this medicine, your doctor will also prescribe another medicine called prednisone or prednisolone. This is to reduce the risk of high blood pressure, fluid retention (water retention), or low potassium levels in your blood.
Do not take this medicine if any of the above applies to you. If you are not sure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before starting treatment with this medicine:
Tell your doctor if you have been told you have any heart or blood vessel disorder, including heart rhythm problems (arrhythmia), or if you are being treated with medicines for these disorders.
Tell your doctor if you have yellowing of the skin or eyes, dark urine, or severe nausea or vomiting, as these can be signs of liver problems. Rarely, liver failure (acute hepatic failure) can occur, which can be life-threatening.
A decrease in red blood cell count, reduced sexual desire, and cases of muscle weakness and/or muscle pain may occur.
This medicine should not be taken in combination with Ra-223 due to a possible increased risk of bone fractures or death.
If you plan to take Ra-223 after treatment with abiraterone and prednisone/prednisolone, you must wait 5 days before starting Ra-223 treatment.
If you are not sure if any of the above applies to you, consult your doctor or pharmacist before taking this medicine.
Blood tests
Abiraterone may affect your liver even if you have no symptoms. While you are taking this medicine, your doctor will regularly perform blood tests to check for any effects on your liver.
Children and adolescents
This medicine must not be used in children or adolescents. If a child or adolescent accidentally ingests abiraterone, they should go to the hospital immediately and bring this leaflet with them to show to the emergency doctor.
Other medicines and Abiraterone Exeltis
Consult your doctor or pharmacist before taking any other medicine.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is important because abiraterone can increase the effects of certain medicines, including heart medicines, sedatives, some diabetes medicines, herbal medicines (e.g., St. John's Wort), and others. Your doctor may consider changing the dose of these medicines. Additionally, some medicines may increase or decrease the effects of abiraterone. This may lead to side effects or abiraterone may not work as well as it should.
Androgen deprivation treatment may increase the risk of heart rhythm problems. Tell your doctor if you are being treated with medicines
Consult your doctor if you are taking any of the medicines listed above.
Abiraterone Exeltis with food
Abiraterone is not indicated in women.
Driving and using machines
It is unlikely that this medicine will affect your ability to drive or use tools or machines.
Abiraterone Exeltis contains lactose and sodium
This medicine contains lactose (a type of sugar). If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
This medicine contains 24 mg of sodium (a major component of cooking/table salt) in each dose of two tablets. This is equivalent to 1.2% of the maximum recommended daily intake of sodium for an adult.
Follow exactly the instructions of your doctor for taking this medicine. If you are not sure, consult your doctor or pharmacist again.
How much to take
The recommended dose is 1,000 mg (two tablets) once a day.
Take prednisone or prednisolone exactly as your doctor tells you.
Your doctor may also prescribe other medicines while you are taking Abiraterone and prednisone or prednisolone.
If you take more Abiraterone Exeltis than you should
If you take more than you should, consult your doctor or go to the hospital immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Abiraterone Exeltis
If you stop taking Abiraterone Exeltis
Do not stop taking this medicine or prednisone or prednisolone unless your doctor tells you to.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking Abiraterone Exeltis and see a doctor immediately if you experience any of the following:
Other side effects are:
Very common(may affect more than 1 in 10 people):
Fluid retention in the legs or feet, low potassium levels in the blood, elevated liver function tests, high blood pressure, urinary tract infection, diarrhea.
Common(may affect up to 1 in 10 people):
High levels of fats in the blood, chest pain, irregular heartbeat (atrial fibrillation), heart failure, rapid heartbeat, severe infections called sepsis, bone fractures, indigestion, blood in the urine, skin rash.
Uncommon(may affect up to 1 in 100 people):
Problems with the adrenal glands (related to problems with salt and water), abnormal heart rhythm (arrhythmia), muscle weakness and/or muscle pain.
Rare(may affect up to 1 in 1,000 people):
Lung irritation (also called allergic alveolitis).
Liver failure (also called acute hepatic failure).
Frequency not known(cannot be estimated from the available data):
Heart attack, changes in the electrocardiogram (ECG) (prolonged QT), and severe allergic reactions with difficulty swallowing or breathing, face, lips, tongue, or throat swelling, or itchy rash.
Bone density loss may occur in men receiving treatment for prostate cancer. Abiraterone Exeltis in combination with prednisone or prednisolone may increase this bone density loss.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Exeltis Healthcare, S.L.
Avda. de Miralcampo, 7
Polígono Industrial Miralcampo,
19200 Azuqueca de Henares, Guadalajara
Spain
Laboratorios León Farma, S.A.
Pol. Ind. Navatejera.
C/ La Vallina s/n
24008 - Villaquilambre, León.
Spain
or
Laboratorios Liconsa, S.A.
Av. Miralcampo, 7,
19200 Azuqueca de Henares, Guadalajara,
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
| Marketing authorization name | |
Netherlands | Abiraterone Leon Farma 500 mg filmomhulde tabletten | |
France | Abiraterone CRISTERS 500 mg film-coated tablets | |
Ireland | Abiraterone Rowa 500 mg film-coated tablets | |
Spain | Abiraterona Exeltis 500 mg comprimidos recubiertos con película EFG | |
Poland | Abiraterone Exeltis |
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.